HeartBeam, Inc. — fact timeline

Branislav Vajdic was appointed as Principal Executive Officer at HeartBeam, Inc..

“Dr. Vajdic, will also serve as the Company’s principal executive officer, effective July 1, 2026.”

Mark Strome resigned as Director at HeartBeam, Inc..

“On June 18, 2026, Mark Strome notified the Company of his resignation from the Board and all committees thereof, effective immediately.”

Robert P. Eno departed as Chief Executive Officer at HeartBeam, Inc..

“On June 18, 2026, Heartbeam, Inc. (the “Company”) and Mr. Eno mutually agreed to his departure as the Company’s Chief Executive Officer, as a member of the Company’s Board of Directors (the “Board”), and as the Company’s principal executive officer, effective as of June 30, 2026”

HeartBeam, Inc. entered into Underwriting Agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC valued at approximately $10.0 million (effective 2026-04-14).

“On April 14, 2026, HeartBeam, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Titan Partners Group LLC, a division of American Capital Partners, LLC (the “Underwriter”), pursuant to which the Company agreed to issue and sell in an underwritten public offering (the “Offering”) an aggregate of 12,500,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”).”

Robert Eno was appointed as Director at HeartBeam, Inc..

“appointed Robert Eno, the Company’s Chief Executive Officer, as a member of the Board effective as of May 5, 2025”

HeartBeam, Inc. engaged CBIZ CPAs P.C. as its auditor.

“the Audit Committee of the Company’s Board of Directors approved the engagement of CBIZ CPAs to serve as the independent registered public accounting firm of the Company for the year ending December 31, 2025, effective immediately.”

Marcum LLP resigned as auditor of HeartBeam, Inc..

“On April 21, 2025, Marcum resigned as the Company’s independent registered public accounting firm, and the Audit Committee of the Company’s Board of Directors approved the engagement of CBIZ CPAs to serve as the independent registered public accounting firm of the Company for the year ending December 31, 2025, effective immediately.”

Branislav Vajdic was appointed as President at HeartBeam, Inc..

“the Board appointed Branislav Vajdic, PhD, Founder and current Chief Executive Officer as President of the Company (the “President Appointment”) effective as of October 21, 2024.”

Robert Eno was appointed as Chief Executive Officer at HeartBeam, Inc..

“On October 17, 2024, the Board of Directors (the “Board”) of HeartBeam, Inc. (the “Company”) appointed Robert Eno as Chief Executive Officer of the Company (the “CEO Appointment”) effective as of October 21, 2024.”

Timothy Cruickshank was appointed as Chief Financial Officer at HeartBeam, Inc..

“On August 22, 2024, the Board of Directors (the “ Board ”) of HeartBeam, Inc. (the “ Company ”) appointed Timothy Cruickshank as Chief Financial Officer of the Company (the “ Appointment ”) effective as of September 9, 2024.”

HeartBeam, Inc. terminated AGP Sales Agreement with A.G.P./Alliance Global Partners (effective 2024-05-01).

“In order to proceed with the PV Sales Agreement, at its sole discretion, on May 1, 2024 the Company terminated its prior Sales Agreement (the “AGP Sales Agreement”) with A.G.P./Alliance Global Partners, as sales agent (“AGP”), having provided AGP with 5 days’ written notice to terminate, in accordance with Section 11(b) of the AGP Sales Agreement.”

HeartBeam, Inc. entered into PV Sales Agreement with Public Ventures, LLC valued at $17,000,000 (effective 2024-05-02).

“On May 2, 2024, HeartBeam, Inc. (the “Company”) entered into a Sales Agreement (the “PV Sales Agreement”) with Public Ventures, LLC, as sales agent (“Public Ventures”), pursuant to which the Company may offer and sell (the “Offering”), from time to time, at its option, through or to Public Ventures, up to an aggregate of approximately $17,000,000 of shares of the Company’s common stock, $0.0001 par value per share (the “Shares”).”

Richard Brounstein retired as Chief Financial Officer at HeartBeam, Inc..

“On December 29, 2023, Richard Brounstein, informed the Company of his plans to retire from his position (the “ Retirement ”) as Chief Financial Officer of HeartBeam, Inc. (the “ Company ” or " HeartBeam ") effective as of February 1, 2024.”

Michael R. Jaff was appointed as director at HeartBeam, Inc..

“On July 24, 2023, the Board of Directors (the “Board”) of HeartBeam, Inc. (the “Company”) approved the appointment of Michael R. Jaff as a director of the Company (the “Appointment”) effective as of July 24, 2023.”

HeartBeam, Inc. shareholders approved Amendment to 2022 Equity Incentive Plan to increase authorized shares from 1,900,000 to 5,900,000 at the 2023-07-07 meeting.

“3. The proposal to amend the 2022 Equity Incentive Plan to increase the number of authorized shares from 1,900,000 shares to 5,900,000 shares: Votes For Votes Against Broker Non-Votes Votes Abstained 13,469,751 788,072 3,460,395 1,055”

HeartBeam, Inc. shareholders approved Ratification of appointment of Marcum LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-07-07 meeting.

“2. The proposal to ratify the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was approved as follows: Votes For Votes Against Broker Non-Votes Votes Abstained 17,691,638 8,471 0 19,164”

HeartBeam, Inc. shareholders approved Election of five nominees for director to serve a one-year term at the 2023-07-07 meeting.

“1.The five nominees for director were elected to serve a one-year term as follows: Director Votes For Votes Against Abstain Broker Non-Vote Richard Ferrari 14,018,463 176,653 63,762 3,460,395 Branislav Vajdic, PhD 14,178,136 26,781 53,961 3,460,395 George A. de Urioste 13,921,915 161,275 175,688 3,460,395 Marga Ortigas-Wedekind 14,180,333 24,414 54,131 3,460,395 Willem Elfrink 14,034,713 160,535 63,630 3,460,395”

Richard Brounstein resigned as Chief Financial Officer at HeartBeam, Inc..

“Additionally, Mr. Brounstein, the Company’s Chief Financial Officer, announced plans to retire and his resignation will be effective October 31, 2023.”

Ken Nelson was appointed as Director at HeartBeam, Inc..

“On June 5, 2023, the Board of Directors (the “Board”) of HeartBeam, Inc. (the “Company”) approved the appointment of Mark Strome and Ken Nelson as directors of the Company (the “Appointments”) effective as of June 5, 2023.”

Mark Strome was appointed as Director at HeartBeam, Inc..

“On June 5, 2023, the Board of Directors (the “Board”) of HeartBeam, Inc. (the “Company”) approved the appointment of Mark Strome and Ken Nelson as directors of the Company (the “Appointments”) effective as of June 5, 2023.”

HeartBeam, Inc. entered into Financial Advisory Agreement with A.G.P./Alliance Global Partners valued at fixed sum of $70,000 (effective 2023-04-27).

“on April 27, 2023, the Company entered into a Financial Advisory Agreement (the “ Financial Advisory Agreement ”) with A.G.P./Alliance Global Partners”

HeartBeam, Inc. entered into Securities Purchase Agreement with an accredited investor valued at 1,000,000 shares of common stock at a price of $1.50 per share, generating net proceeds of approxima (effective 2023-05-02).

“On May 2, 2023, HeartBeam, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ SPA ”) with an accredited investor”

HeartBeam, Inc. entered into Subscription Agreement with the investors signatory thereto (the "Investor") valued at $23.2 million (effective 2023-05-02).

“A Subscription Agreement, dated as of May 2, 2023 between the investors signatory thereto (the "Investor") and the Company whereby the Investor agrees to buy and the Company agrees to sell to Investor such number of shares of Common Stock set forth on the signature page”

HeartBeam, Inc. entered into Placement Agency Agreement with Public Ventures, LLC (effective 2023-04-20).

“Placement Agency Agreement dated as of April 20, 2023 between the Company and Public Ventures, LLC (the "Placement Agent")”

HeartBeam, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“March 20, 2023, HeartBeam, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Stock Market to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. In its annual report on Form 10-K for the period ended December 31, 2022, the Company reported stockholders’ equity of $2,374,000, and, as a result, does not currently satisfy Listing Rule 5550(b)(1). Nasdaq’s letter has no immediate impact on the listing of the Company’”

HeartBeam, Inc. amended First Amendment to Note Purchase Agreement with Maverick Capital Partners, LLC valued at reduce the principal amount of the Convertible Notes available for sale from $5,000,000 to $4,000,00 (effective 2023-03-07).

“On March 7, 2023, the parties to the NPA entered into a First Amendment to Note Purchase Agreement (the “NPA Amendment No. 1”, together with the SPA Amendment No. 1, the “Amendments”) pursuant to which the parties agreed to reduce the principal amount of the Convertible Notes available for sale from $5,000,000 to $4,000,000.”

HeartBeam, Inc. amended Amendment to Securities Purchase Agreement with Maverick Capital Partners, LLC valued at reduce the total value of the Shares available for sale from $5,000,000 to $4,000,000 (effective 2023-03-07).

“On March 7, 2023, the parties to the SPA entered into an Amendment to Securities Purchase Agreement (the “SPA Amendment No. 1”) pursuant to which the parties agreed to reduce the total value of the Shares available for sale from $5,000,000 to $4,000,000.”

HeartBeam, Inc. entered into note purchase agreement with Maverick Capital Partners, LLC valued at up to $5,000,000 principal amount (effective 2023-02-28).

“On February 28, 2023, in connection with the SPA, the Company entered into a note purchase agreement (the “NPA”) with the Investor. Pursuant to the terms of the NPA, the Company agreed to sell, up to $5,000,000 principal amount of notes of the Company, bearing interest at 6% per annum (the “Convertible Notes”).”

HeartBeam, Inc. entered into Securities Purchase Agreement with Maverick Capital Partners, LLC valued at up to $5,000,000 (effective 2023-02-28).

“On February 28, 2023, HeartBeam, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “SPA”) with Maverick Capital Partners, LLC (the “Investor”), pursuant to which the Company agreed to sell, up to $5,000,000 (the “Shares”) of the Company’s common stock”

Jon Hunt departed as Chief Business Officer at HeartBeam, Inc..

“Effective March 15, 2023, Jon Hunt, Ph.D. will resign from his position as Chief Business Officer of HeartBeam, Inc. (the “ Company ” or " HeartBeam ") and transition (the “ Transition ”) to a new non-officer position as a Consultant effective as of March 16, 2023.”

HeartBeam, Inc. entered into NPA with Maverick Capital Partners, LLC valued at up to $5,000,000 (effective 2023-02-28).

“Additionally, in connection with the SPA, on February 28, 2023, the Company entered into a note purchase agreement (the “NPA”) with the Investor. Pursuant to the terms of the NPA, the Company agreed to sell, up to $5,000,000 principal amount of notes of the Company, bearing interest at 6% per annum (the “Convertible Notes”).”

HeartBeam, Inc. entered into SPA with Maverick Capital Partners, LLC valued at up to $5,000,000 (effective 2023-02-28).

“On February 28, 2023, HeartBeam, Inc. (the “Company”) entered into a securities purchase agreement (the “SPA”) with Maverick Capital Partners, LLC (the “Investor”). Pursuant to the terms of the SPA, the Company agreed to sell, up to $5,000,000 (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) at 75% of the average calculated Volume Weighted Average Price (“VWAP”) per share during a Drawdown Pricing Period (as defined in the SPA).”

HeartBeam, Inc. entered into Sales Agreement with A.G.P./Alliance Global Partners valued at approximately $13,000,000 (effective 2023-02-01).

“On February 1, 2023, HeartBeam, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with A.G.P./Alliance Global Partners, as sales agent (“A.G.P.”), pursuant to which the Company may offer and sell (the “Offering”), from time to time, at its option, through or to A.G.P., up to an aggregate of approximately $13,000,000 of shares of the Company’s common stock, $0.0001 par value per share (the “Shares”).”

Robert P. Eno was appointed as President at HeartBeam, Inc..

“On January 18, 2023, the Board of Directors (the “ Board ”) of HeartBeam, Inc. (the “ Company ”) appointed Robert P. Eno as President of the Company (the “ Appointment ”) effective as of January 18, 2023.”

HeartBeam, Inc.: Amended Certificate of Incorporation to increase authorized Common Stock to 100,000,000 and authorize 10,000,000 shares of blank check Preferred Stock (effective 2022-11-16).

“The amendment to the Certificate of Incorporation became effective upon filing with, and acceptance for record by, the Secretary of State of Delaware on November 16, 2022.”

Ken Persen was appointed as Chief Technical Officer at HeartBeam, Inc..

“On August 2, 2022, the Board of Directors (the “ Board ”) of the Company appointed Ken Persen as Chief Technical Officer of the Company (the “ Appointment ”) effective as of August 2, 2022.”

Alan Baumel was appointed as Chief Operating Officer at HeartBeam, Inc..

“On December 20, 2021, the Board of Directors (the “Board”) of HeartBeam, Inc. (the “Company”) appointed Alan Baumel as Chief Operating Office of the Company (the “Appointment”) effective as of December 20, 2021.”